TY - JOUR
T1 - Serum amyloid A induction in tumor-bearing mice
T2 - Evidence for a tumor- derived mediator
AU - Ghezzi, P.
AU - Bertini, R.
AU - Bianchi, M.
AU - Erroi, A.
AU - Mengozzi, M.
AU - Delgado, R.
AU - Giavazzi, R.
AU - Bartle, L.
AU - Sipe, J. D.
PY - 1993
Y1 - 1993
N2 - Increases in the concentration of various acute-phase serum proteins synthesized by the liver, including serum amyloid A (SAA) have been reported in cancer patients or tumor-bearing animals. The induction of SAA has been shown, from studies of endotoxin-induced inflammation, to be mediated by cytokines, including interleukins 1 and 6 (IL-1 and IL-6) and tumor necrosis factor (TNF). We have found increased SAA levels in mice transplanted with a variety of tumors, and used the S-180 sarcoma to investigate the mechanism of SAA induction of cancer; this appeared to be independent of immunogenicity since elevated SAA concentrations were also observed in tumor-bearing nude mice. The following evidence was obtained indicating that an endogenous mediator produced by the tumor was responsible for cancer-associated SAA induction: a) SAA concentrations returned to baseline after surgical removal of the tumor; b) injection of serum obtained from tumor-bearing mice into healthy mice induced SAA levels with a maximal induction 24h after injection; c) injection of supernatants from in vitro cultures of S-180 tumor cells also induced SAA in healthy mice; d) serum from tumor-bearing mice or supernatants from S-180 cell cultures was capable of inducing SAA synthesis in vitro by the human hepatoma cell line Hep3B. The putative cancer associated SAA inducer is non dialyzable, heat-labile and has a molecular mass of approximately 8-12 kD.
AB - Increases in the concentration of various acute-phase serum proteins synthesized by the liver, including serum amyloid A (SAA) have been reported in cancer patients or tumor-bearing animals. The induction of SAA has been shown, from studies of endotoxin-induced inflammation, to be mediated by cytokines, including interleukins 1 and 6 (IL-1 and IL-6) and tumor necrosis factor (TNF). We have found increased SAA levels in mice transplanted with a variety of tumors, and used the S-180 sarcoma to investigate the mechanism of SAA induction of cancer; this appeared to be independent of immunogenicity since elevated SAA concentrations were also observed in tumor-bearing nude mice. The following evidence was obtained indicating that an endogenous mediator produced by the tumor was responsible for cancer-associated SAA induction: a) SAA concentrations returned to baseline after surgical removal of the tumor; b) injection of serum obtained from tumor-bearing mice into healthy mice induced SAA levels with a maximal induction 24h after injection; c) injection of supernatants from in vitro cultures of S-180 tumor cells also induced SAA in healthy mice; d) serum from tumor-bearing mice or supernatants from S-180 cell cultures was capable of inducing SAA synthesis in vitro by the human hepatoma cell line Hep3B. The putative cancer associated SAA inducer is non dialyzable, heat-labile and has a molecular mass of approximately 8-12 kD.
KW - Acute-phase proteins
KW - sarcoma 180
KW - serum amyloid A
UR - http://www.scopus.com/inward/record.url?scp=0027749288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027749288&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0027749288
VL - 6
SP - 169
EP - 186
JO - International Journal of Immunopathology and Pharmacology
JF - International Journal of Immunopathology and Pharmacology
SN - 0394-6320
IS - 3
ER -